Kelun-Biotech's Sac-TMT OS Data Confirms Survival Benefit in EGFR-Mutant NSCLC
Event summary
- Kelun-Biotech will present final overall survival (OS) analysis from the OptiTROP-Lung03 study at the 2026 European Lung Cancer Congress (ELCC) in Copenhagen.
- The OptiTROP-Lung03 study demonstrated a median OS of 20.0 months for sac-TMT vs. 11.2 months for docetaxel (HR 0.45, 95% CI: 0.28–0.73) after adjusting for crossover treatment.
- Sac-TMT has already received NMPA approval for this indication and is included in China's National Reimbursement Drug List (NRDL).
- The OptiTROP-Lung04 study showed a median OS of 20 months for sac-TMT in EGFR-mutant NSCLC patients post-EGFR-TKI and platinum-based chemotherapy.
The big picture
Kelun-Biotech's sac-TMT represents a significant advancement in the treatment of EGFR-mutant NSCLC, a market with substantial unmet need and growing competition. The consistent positive data across multiple trials, coupled with NMPA approval and reimbursement, positions sac-TMT as a leading therapeutic option in China. However, the company's reliance on Merck for global commercialization outside of China introduces a dependency that could impact long-term revenue potential.
What we're watching
- Crossover Impact
- The significant crossover of patients from the docetaxel group to sac-TMT raises questions about the true impact of the initial treatment arms and necessitates careful interpretation of the adjusted OS data.
- Global Expansion
- The licensing agreement with Merck & Co. suggests a potential for broader global commercialization; however, the success of sac-TMT outside of China remains to be seen.
- Clinical Adoption
- The pace at which clinicians adopt sac-TMT, particularly given its inclusion in the NRDL, will be a key indicator of its long-term market penetration and revenue generation.
Related topics